China NMPA Product Recall - Nucleic Acid Extraction or Purification Reagents NucliSENS easyMAG Accessory Products

On July 18, 2022, the National Medical Products Administration (NMPA) announced a voluntary recall initiated by BIOMERIEUX S.A., a medical device manufacturer, as reported by its local entity, BIOMERIEUX Diagnostics Products (Shanghai) Co., Ltd. The recall targets specific models and batches of the NucliSENS easyMAG Accessory Products, which are crucial for nucleic acid extraction or purification in diagnostic procedures. The identified issue involves a significant malfunction where these products may produce delayed or entirely absent results when processing Legionella nucleic acids. This defect poses a considerable risk to accurate and timely diagnosis, potentially affecting patient treatment decisions. Operating within the NMPA's regulatory framework, BIOMERIEUX S.A. has classified this as a Level II recall, indicating a situation where the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. The required action involves the company retrieving the affected products from the market and implementing corrective measures to ensure the reliability and safety of their diagnostic tools. Further specifics regarding recall numbers, product specifications, and batch identifiers are detailed in the official Medical Device Recall Event Report Form.